Market Research Logo
Region: Europe
Category: Country Overviews

Europe Country Overviews

(142 reports matching your criteria)
  • Slovakia Pharmaceuticals and Healthcare Report Q2 2016

    ... accelerate, givenSlovakia's ageing population and burden of chronic diseases. With public finances on a firmer footing and acentre-left government promising more generous social spending, multinational drugmakers and medicaldevice companies can expect to see growth in ... Read More

  • Slovenia Pharmaceuticals and Healthcare Report Q2 2016

    ... the impact of revenue declines for the shortterm. We expect a continued focus on cost containment by European healthcare payers to moderate Krka'sgrowth outlook over the longer term, unless the company looks to geographically diversify ... Read More

  • Estonia Pharmaceuticals and Healthcare Report Q2 2016

    ... insurer to accommodatefurther healthcare spending growth and BMI's outlook for the country's economy over the long term. Drugmakers can expect to see constrained revenue growth in the country as pricing pressures andrestrictive drug reimbursement are ... Read More

  • France Pharmaceuticals and Healthcare Report Q2 2016

    ... growth rates. However,supply side factors will continue to weigh negatively on fixed investment rates in the pharmaceuticalindustry, as labour market structural deficiencies are not expected to recede in the foreseeable future. Morebroadly, as pharmaceutical firms ... Read More

  • Ireland Pharmaceuticals and Healthcare Report Q2 2016

    ... job creationin both the pharmaceutical and healthcare industries. While pharmaceutical exports will continue to besupported by Ireland's main export markets growth, including the US, the UK and Western Europe, thedomestic Irish market, albeit small in ... Read More

  • Belgium Pharmaceuticals and Healthcare Report Q2 2016

    ... as it struggles to hit its fiscal targets. Headline Expenditure Projections Pharmaceuticals: From EUR5.84bn (USD6.42bn) in 2015 to EUR5.89bn (USD6.30bn) in 2016; +1.0%in local currency terms and -1.8% in US dollar terms. Healthcare: From EUR44.96bn ... Read More

  • Bulgaria Pharmaceuticals and Healthcare Report Q2 2016

    ... cost-saving measures to reduce the budgetdeficit. Such controls to healthcare spending will produce a bleak outlook for pharmaceutical andhealthcare providers. Headline Expenditure Projections Pharmaceuticals: BGN2.71bn (USD1.52bn) in 2015 to BGN2.89bn (USD1.58bn) in 2016; +6.7% inlocal ... Read More

  • Hungary Pharmaceuticals and Healthcare Report Q2 2016

    ... the migrantcrisis have caused the healthcare system to be labelled as in a critical condition. Headline Expenditure Projections Pharmaceuticals: HUF660.80bn (USD2.37bn) in 2015 to HUF668.00bn (USD2.28bn) in 2016; +1.1%in local currency terms and -3.5% in ... Read More

  • Lithuania Pharmaceuticals and Healthcare Report Q2 2016

    ... to anincrease in sales; however, fiscal policies and the small size of the market will limit revenue earningopportunities. Headline Expenditure Projections Pharmaceuticals: EUR616mn (USD677mn) in 2015 to EUR638mn (USD682mn) in 2016; +3.6% inlocal currency terms ... Read More

  • Germany Pharmaceuticals and Healthcare Report Q2 2016

    ... and social security payments, will appeal to multinationaldrugmakers. Furthermore, in order to mitigate Germany's dire demographics and growing social securityspending brought about by an ageing population, there has been a broader trend in the introduction ... Read More

  • Latvia Pharmaceuticals and Healthcare Report Q2 2016

    ... cuts and place more emphasis on the private sector. Growth in the pharmaceutical sector will belimited by an increasing preference for generic substitution despite a transparent regulatory environment. 0Headline Expenditure Projections Pharmaceuticals: EUR338mn (USD372mn) in ... Read More

  • Croatia Pharmaceuticals and Healthcare Report Q2 2016

    ... towards growth and reduce the use of high-value patented drugs, highlighting minimal revenueearning opportunities for multinational pharmaceutical firms. Headline Expenditure Projections Pharmaceuticals: HRK6.73bn (USD961mn) in 2015 to HRK6.76bn (USD931mn) in 2016; 0.5% inlocal currency and ... Read More

  • Sweden Pharmaceuticals and Healthcare Report Q2 2016

    ... conditions will increase over the next 15 years. Presenting a challenge to drugmakers,like many other developed states, Sweden is introducing cost-containment measures to restrict thecommercial opportunities available to drugmakers. Headline Expenditure Projections Pharmaceuticals: SEK39.50bn (USD4.68bn) ... Read More

  • Austria Pharmaceuticals and Healthcare Report Q2 2016

    ... to publicspending in particular. However, the country's economy is poised to grow in 2016 and therefore, we believepharmaceutical spending will post modest growth over the medium term, as the government links growth inpublic healthcare expenditure ... Read More

  • Denmark Pharmaceuticals and Healthcare Report Q2 2016

    ... 2016 in local currency terms, especially as economic conditions improve. The demand forinnovative medicines and high quality healthcare services will be driven by the country's aging populationand high per capita spending. However, in the long-term ... Read More

  • Italy Pharmaceuticals and Healthcare Report Q2 2016

    ... increase, as will consumerconfidence and this will provide a boost to the retail sector. However, because the recovery will berelatively tepid, we believe that essential spending will increase more rapidly than non-essential spending. Low inflation ... Read More

  • Belarus Pharmaceuticals and Healthcare Report Q2 2016

    ... the form of domestic bias in the medicine tendering process and pricing controls, willfurther reduce revenue earning opportunities. Additional risks include a continued poor economic forecastand rising regional geopolitical tensions. Headline Expenditure Projections Pharmaceuticals: BYR12,247bn ... Read More

  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2016

    ... outlook will be the driving factor behindgrowth, with plans to further increase access to healthcare; pharmaceutical sales are expected to increaseover the coming years. Headline Expenditure Projections Pharmaceuticals: CZK78.83bn (USD3.01bn) in 2015 to CZK81.10bn (USD3.27bn) ... Read More

  • Greece Pharmaceuticals and Healthcare Report Q1 2016

    ... medicines to 40% will failto produce the desired generic medicine uptake in the face of austerity. The government's focus onincreasing the consumption of generic medicines alongside persistent debt problems within the healthsystem highlights Greece as ... Read More

  • United Kingdom Pharmaceuticals and Healthcare Report Q1 2016

    ... to cost containmentmeasures, the adoption of health innovations will continue to be a competing policy priority, as illustratedby the recent creation of a market access office under the National Institute for Health and Care Excellenceto ... Read More

  • Sweden Pharmaceuticals and Healthcare Report Q1 2016

    ... per capita spending, multinationalpharmaceutical companies will continue to be provided with steady revenue-earning opportunities. Suchdemographic trends will remain the primary driver of growth behind the prescription drug markets thoughwe highlight that the government is likely ... Read More

  • Netherlands Pharmaceuticals and Healthcare Report Q4 2015

    ... will provide a small boost to pharmaceutical sales in the near term. We forecast thepharmaceutical market will return to growth in 2016, the first time since 2011. Over the long term,medicine demand will be driven ... Read More

  • Lithuania Pharmaceuticals and Healthcare Report Q3 2015

    ... will support growth in spending on consumer healthcare products,namely OTC medicines. Headline Expenditure Projections Pharmaceuticals: EUR601mn (USD806mn) in 2014 to EUR618mn(USD680mn) in 2015; +2.7% inlocal currency terms and -15.7% in US dollar terms. Forecast revised ... Read More

  • Norway Pharmaceuticals and Healthcare Report Q3 2015

    ... manufacturers in the foreseeable future. Despite a comparativelysmaller market size, Norway's pharmaceutical sector, as distinct from several contracting drug markets inthe region, is expected to continue on its long-standing positive growth trajectory, creating opportunitiesfor drugmakers. ... Read More

  • Finland Pharmaceuticals and Healthcare Report Q3 2015

    ... high-value drugs in the medium-term. However,rising healthcare costs will place a heavy burden on government finances, requiring patented drug makersto prove the cost-effectiveness of their medicines over less expensive generic drugs. Headline Expenditure Projections Pharmaceuticals: ... Read More

1 2 4 6